Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing Klebsiella pneumoniae

Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae

(2018) Young R. Lee et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

(2018) Konstantinos Z Vardakas et al.   LANCET INFECTIOUS DISEASES

Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient

(2018) Nuria Piedra-Carrasco et al.   Microbial Drug Resistance

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

(2017) M. Souli et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)

(2017) Alessandra Oliva et al.   JOURNAL OF INFECTION

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

(2017) Belén Gutiérrez-Gutiérrez et al.   LANCET INFECTIOUS DISEASES

Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice

(2017) Veena Venugopalan et al.   Infectious Diseases

Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials

(2016) Jason A. Roberts et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

(2016) David van Duin et al.   CLINICAL INFECTIOUS DISEASES

Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae

(2016) A. Oliva et al.   CLINICAL MICROBIOLOGY AND INFECTION

Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia

(2015) Jose F. Camargo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae

(2015) Jessica B. Cprek et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Managing a nosocomial outbreak of carbapenem-resistantKlebsiella pneumoniae: an early Australian hospital experience

(2015) L. W. K. Chang et al.   INTERNAL MEDICINE JOURNAL

Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen

(2015) Alessandra Oliva et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

(2015) Mario Tumbarello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitroevaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae

(2015) Laurent Poirel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae

(2015) Nathalie Grace Chua et al.   JOURNAL OF INFECTION

Treating infections caused by carbapenemase-producing Enterobacteriaceae

(2014) L.S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches

(2014) Ilias Karaiskos et al.   EXPERT OPINION ON PHARMACOTHERAPY

Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections

(2014) A. Oliva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Successful Ertapenem-Doripenem Combination Treatment of Bacteremic Ventilator-Associated Pneumonia Due to Colistin-Resistant KPC-Producing Klebsiella pneumoniae

(2013) Giancarlo Ceccarelli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae

(2013) Helen Giamarellou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria

(2013) Konstantinos Pontikis et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae

(2012) Kenneth S. Thomson   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nosocomial Outbreak of Klebsiella pneumoniae Carbapenemase-Producing Klebsiella oxytoca in Austria

(2012) Martin Hoenigl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Klebsiella Pneumoniae Carbapenemase (KPC) infections: a review of published case series and case reports

(2012) Grace C Lee et al.   Annals of Clinical Microbiology and Antimicrobials

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

(2009) Abraham Borer et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

(2009) Patrice Nordmann et al.   LANCET INFECTIOUS DISEASES